Glaxosmithkline Investigacion y Desarrollo SL

Where the EU money came from

Funding by EU programme. Amounts are Glaxosmithkline Investigacion y Desarrollo SL's own share of each project, not the project's full budget.

Projects

22 EU-funded projects, newest first. Glaxosmithkline Investigacion y Desarrollo SL led 6 of them as coordinator. Each links to the official record.

• CUREMALCoordinator

  Innovative Transformative CURE for MALaria: Rapid-Action Combinations to Replace Artemisinins

  Horizon Europe · 2026–2030 · Project on CORDIS ↗
• END2AMRPartner

  European Novel Drug research to Address Microbial infections and drug Resistance

  Horizon Europe · 2026–2030 · Project on CORDIS ↗
• EX-DR TBPartner

  EX-DR TB: Elimination of Extensive Drug Resistance Through better Regimens for TB

  Horizon Europe · 2025–2031 · Project on CORDIS ↗
• DEFENDCoordinator

  Delftia TsuruhatensTC1 Based-Intervention For Interrupting Malaria Transmission In Mosquitoes: A Novel Trial For Evaluating Alternative Tools For Control Of Vector-Borne Diseases

  Horizon Europe · 2025–2030 · Project on CORDIS ↗

  €1.1Mtheir share
• PIAPartner

  Photocatalytic Industrial Applications

  Horizon Europe · 2025–2028 · Project on CORDIS ↗
• NAVIPPPartner

  New AntiVirals for Infections with Pandemic Potential

  Horizon Europe · 2024–2028 · Project on CORDIS ↗

  €1.1Mtheir share
• ITHEMYCPartner

  Novel immunotherapies for tuberculosis and other mycobacterial diseases

  Horizon Europe · 2023–2027 · Project on CORDIS ↗

  €760ktheir share
• UNITE4TBPartner

  ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS

  Horizon 2020 · 2021–2028 · Project on CORDIS ↗
• ERA4TBPartner

  EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS

  Horizon 2020 · 2020–2026 · Project on CORDIS ↗
• GNA NOWPartner

  NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

  Horizon 2020 · 2019–2026 · Project on CORDIS ↗
• TRIC-TBPartner

  Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.

  Horizon 2020 · 2019–2024 · Project on CORDIS ↗
• LYMPHVECsCoordinator

  Development of lipid nanoparticles based on solid matrix for Benznidazole oral delivery targeting to the lymphatic system to treat Chagas disease

  Horizon 2020 · 2019–2021 · Project on CORDIS ↗

  €158ktheir share
• I-CONSENTAssociated partner

  Improving the guidelines for Informed Consent, including vulnerable populations, under a gender perspective

  Horizon 2020 · 2017–2021 · Project on CORDIS ↗
• anTBioticCoordinator

  AnTBiotic – progressing TB drug candidates to clinical proof of concept

  Horizon 2020 · 2017–2022 · Project on CORDIS ↗

  €705ktheir share
• NAREBPartner

  Nanotherapeutics for antibiotic resistant emerging bacterial pathogens

  FP7 (2007 to 2013) · 2014–2018 · Project on CORDIS ↗

  €810ktheir share
• COOPERA-TBPartner

  Hit to lead optimisation of novel anti-TB scaffolds through an academic-industrial partnership

  FP7 (2007 to 2013) · 2014–2018 · Project on CORDIS ↗

  €15ktheir share
• OPENMEDCHEMPartner

  Medicinal Chemistry Open Innovation Doctorates

  FP7 (2007 to 2013) · 2012–2016 · Project on CORDIS ↗

  €342ktheir share
• PARAMETPartner

  A systematic analysis of parasite metabolism - from metabolism to intervention

  FP7 (2007 to 2013) · 2012–2016 · Project on CORDIS ↗

  €197ktheir share
• PREDICT-TBCoordinator

  Model-based preclinical development of anti-tuberculosis drug combinations

  FP7 (2007 to 2013) · 2012–2017 · Project on CORDIS ↗
• FISHFORPHARMAPartner

  Training Network on Zebrafish Infection Models for Pharmaceutical Screens

  FP7 (2007 to 2013) · 2012–2015 · Project on CORDIS ↗

  €197ktheir share
• UPSTREAMPartner

  European Research Training in the Ubiquitin Proteasome System

  FP7 (2007 to 2013) · 2011–2015 · Project on CORDIS ↗

  €256ktheir share
• ORCHIDCoordinator

  Open Collaborative Model for Tuberculosis Lead Optimisation

  FP7 (2007 to 2013) · 2011–2015 · Project on CORDIS ↗

  €1.4Mtheir share

Works most with

Organisations that shared the most EU projects with this one. A good starting list for consortium partners.

• Global Alliance for Tb Drug Development Non Profit OrganisationUnited States · 6 shared projects
• Centre National de la Recherche Scientifique CNRSFrance · 5 shared projects
• Forschungszentrum Borstel Leibniz LungenzentrumGermany · 5 shared projects
• Institut National de la Sante et de la Recherche MedicaleFrance · 4 shared projects
• Uppsala UniversitetSweden · 4 shared projects
• The University of LiverpoolUnited Kingdom · 4 shared projects
• Commissariat A L Energie Atomique et aux Energies AlternativesFrance · 3 shared projects
• Agencia Estatal Consejo Superior de Investigaciones CientificasSpain · 3 shared projects
• Ecole Polytechnique Federale de LausanneSwitzerland · 3 shared projects
• University College LondonUnited Kingdom · 3 shared projects
• Erasmus Universitair Medisch Centrum RotterdamNetherlands · 3 shared projects
• Institut PasteurFrance · 3 shared projects
• University of DundeeUnited Kingdom · 3 shared projects
• Department of HealthUnited Kingdom · 3 shared projects
• Stichting LygatureNetherlands · 3 shared projects
• Janssen Pharmaceutica NVBelgium · 3 shared projects

Fields it works in

Research fields recorded on its Horizon projects.

• HIV
• RNA viruses
• animal husbandry
• antibiotic resistance
• antibiotics
• antivirals
• artificial intelligence
• bacteriology
• civil society
• diabetes
• drug discovery
• drug resistance
• embryology
• gender equality